AIM ImmunoTech Inc.
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
AIM | NYSE
Overview
Corporate Details
- ISIN(s):
- US42366C3016
- LEI:
- Country:
- United States of America
- Address:
- 2117 SW HIGHWAY 484, 32801 OCALA
- Website:
- https://aimimmuno.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for cancers, immune disorders, and viral diseases. The company's lead program is Ampligen® (rintatolimod), a proprietary immuno-modulator that has demonstrated broad-spectrum activity and is being evaluated in clinical studies for various debilitating and life-threatening conditions. AIM ImmunoTech is dedicated to advancing therapeutic solutions by leveraging immunology to address unmet medical needs. The company was formerly known as Hemispherx Biopharma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all AIM ImmunoTech Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for AIM ImmunoTech Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for AIM ImmunoTech Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
